CLAIMS

1. A compound of formula (I) or (II) below



(I)



(II)

wherein the hydroxyl groups, each independently, and the amino group, in both formulae (I) or (II) may be optionally protected with suitable hydroxy and/or amino protecting groups; and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein the suitable hydroxy protecting groups are selected from acyloxy, allyloxy, allylcarbonyloxy or arlylalkyloxy groups.

3. A compound according to claim 2 wherein the suitable hydroxy protecting groups are selected from acetyloxy, allyloxy, allylcarbonyloxy, benzyloxy and p.nitrobenzyloxy.

4. A compound according to claim 1 wherein the suitable amino protecting groups are selected from alkoxycarbonylamino or allyloxycarbonylamino.

5. A compound according to claim 4 wherein the suitable amino protecting groups are selected from tert-butoxycarbonylamino (boc-amino) and allyloxycarbonylamino.

6. Use of the compounds of formula (I) and (II), according to claim 1, as scaffolds for combinatorial libraries.

7. A process for preparing the compounds of formula (I), as defined in claim 1, which process comprises the reaction pathway of scheme (1):

Scheme 1



8. A process for preparing the compounds of formula (I), as defined in claim 1, which process comprises the reaction pathway of scheme (2):

Scheme 2



9. A process for preparing the compounds of formula (II), as defined in claim 1, which process comprises the reaction pathway of scheme (3):

Scheme 3



10. A process according to any one of claims from 7 to 9 wherein the following codes have been used to identify functional groups and reactants thereof: (Bn) benzyl;

(CSA) Camphosulfonic acid; (DCM) dichloromethane; (DMF) N,N'-dimethyl-formamide; (Me) methyl; (Ph) phenyl; (PNB) paranitrobenzoyl; (TBDMS) tertbutyl-dimethyl-silyl; (TFA) trifluoroacetic acid.

11. A library of two or more compounds of formula (XXVII) or of formula (XXVIII)



(XXVII)



(XXVIII)

wherein

R_1, R_2 and R_3 are, the same or different and independently from each other, a hydrogen atom or a group of formula (XXIX)

$$-X-R_6 \quad \text{(XXIX)}$$

wherein X is a single bond or a divalent group selected from -CO-, -CS-, -CONR'- or -CSNR'-;

R' and R_6 are, the same or different and independently in each occasion, a hydrogen atom or an optionally substituted group selected from:

a) straight or branched C_1-C_8 alkyl;

b) C_3-C_6 cycloalkyl or C_3-C_6 cycloalkyl-alkyl;

c) aryl or arylalkyl;

d) heterocyclyl or heterocyclylalkyl;

or R' and R_6, taken together with the nitrogen atom to which they are attached, form an optionally substituted 5 to 7 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from N, NH, O or S; or alternatively, any one of R_1 and R_2 or R_1 and R_3 may be linked together so as to form a 5 to 7 membered heterocycle comprising two oxygen atoms, through an alkylene chain $-(CH_2)_m-$ wherein m is an integer from 1 to 3;

R_4 and R_5 are, the same or different and independently from each other, a hydrogen atom or a group of formula (XXX)

$$-Y-R_6 \quad \text{(XXX)}$$

wherein Y is a single bond or a divalent group selected from -CO-, -CS-, -SO_2-, -CONR'-, -CSNR'- or -COO-;

R' and R_6, the same or different and independently in each occasion, are as above defined or, alternatively

R_4 and R_5, taken together with the nitrogen atom to which they are attached, form an optionally substituted 5 to 7 membered heterocycle, optionally containing one additional heteroatom or heteroatomic group selected from N, NH, O or S;

and pharmaceutically acceptable salts thereof.

12. A library according to claim 11 wherein R' and R_6 groups within formulae (XXVII) and (XXVIII) are selected from optionally substituted alkyl, arylalkyl, aryl, or cycloalkyl groups.

13. A library according to claim 12 wherein R' and R_6 groups within formulae (XXVII) and (XXVIII) are selected from optionally substituted ethyl; isopropyl; n-heptyl; n-butyl; methoxymethyl; dimethylaminomethyl; benzyl; p.methoxyphenylmethyl; 2-phenylethyl; α-napthylmethyl; phenyl; 3,5-dimethoxyphenyl; p.methylphenyl; p.fluorophenyl; m.fluoromethyl; m.methoxyphenyl; pyridyl-3-yl; thienyl-2-yl; or cyclopropyl.

14. A library according to claim 11 wherein pharmaceutically acceptable salts of the compounds of formula (XXVII) and (XXVIII) are selected from acid addition salts with nitric, hydrochloric, hydrobromic, sulfuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid, as well as the salts with sodium, potassium, calcium or magnesium hydroxides, carbonates or bicarbonates, methylamine, ethylamine, diethylamine, triethylamine or piperidine.

15. A library according to claim 11 of two or more compounds of formula (XXVII).

16. A library according to claim 15 wherein R_4 and R_5 are both hydrogen atoms.

17. A library according to claim 16 comprising two or more compounds of formula (XXVII-A-) as defined in Chart A.

18. A library according to claim 15 wherein one of R_4 or R_5 is a hydrogen atom or an arylalkyl group and the remaining of R_4 and R_5 is a group of formula (XXX) wherein Y is a divalent -CO- or -SO_2- group and R_6 is as defined in claim 11.

19. A library according to claim 18 comprising two or more compounds of formula (XXVII-B-) as defined in Chart B.

20. A library according to claim 15 wherein one of R_4 or R_5 is a hydrogen atom and the remaining of R_4 and R_5 is a group of formula (XXX) wherein Y is a divalent -CONR'- or -CSNR'- group and R' and R_6 are as defined in claim 11.

21. A library according to claim 20 comprising two or more compounds of formula (XXVII-C-) as defined in Chart C.

22. A method to identify a protein kinase inhibitor, or a polymerase pr protease inhibitor of viral or bacterial pathogens, which method comprises screening a combinatorial library of compounds of formula (XXVII) or (XXVIII), according to claim 11, towards the said protein kinase, polymerase or protease.

23. A compound having formula (XXVII) or (XXVIII) as identified through the screening method of claim 22.

24. Use of a compound of formula (XXVII) or (XXVIII) with protein kinase inhibiting activity, as identified through the screening method of claim 22, in the preparation of a medicament for treating disorders caused by or associated with an altered protein kinase activity.

25. Use according to claim 24 for the treatment of tumors.